-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Monte Rosa Therapeutics (NASDAQ:GLUE) Lifted to "Overweight" at Wells Fargo & Company
Monte Rosa Therapeutics (NASDAQ:GLUE) Lifted to "Overweight" at Wells Fargo & Company
Wells Fargo & Company upgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat reports. Wells Fargo & Company currently has $18.00 target price on the stock.
A number of other research firms have also commented on GLUE. Credit Suisse Group dropped their price target on shares of Monte Rosa Therapeutics to $12.00 in a research report on Wednesday, November 16th. UBS Group began coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 13th. They issued a buy rating and a $22.00 price target on the stock.
Get Monte Rosa Therapeutics alerts:Monte Rosa Therapeutics Stock Down 0.6 %
Shares of GLUE opened at $7.70 on Monday. The firm's 50 day moving average price is $8.51 and its 200 day moving average price is $8.75. Monte Rosa Therapeutics has a twelve month low of $6.05 and a twelve month high of $18.16.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.03. As a group, equities analysts forecast that Monte Rosa Therapeutics will post -2.28 earnings per share for the current fiscal year.Institutional Investors Weigh In On Monte Rosa Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Monte Rosa Therapeutics by 24.8% in the third quarter. Bank of New York Mellon Corp now owns 87,632 shares of the company's stock worth $716,000 after acquiring an additional 17,424 shares during the last quarter. Alphabet Inc. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $11,961,000. Balyasny Asset Management LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $155,000. Jane Street Group LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $410,000. Finally, State Street Corp boosted its stake in Monte Rosa Therapeutics by 7.5% during the third quarter. State Street Corp now owns 484,571 shares of the company's stock worth $3,959,000 after buying an additional 33,707 shares in the last quarter. Institutional investors and hedge funds own 83.19% of the company's stock.
Monte Rosa Therapeutics Company Profile
(Get Rating)
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
Featured Stories
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
- Will Trade Desk Inc Bounce Off Its Support Line?
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Wells Fargo & Company upgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) from an equal weight rating to an overweight rating in a research note published on Monday morning, Marketbeat reports. Wells Fargo & Company currently has $18.00 target price on the stock.
富國銀行升級股份 蒙特羅莎治療 (NASDAQ: 膠 — 獲得評級) Marketbeat 報告從星期一早上發表的研究摘要中的同等體重評級到超重評級。富國銀行公司目前的股票目前有 18.00 美元的目標價。
A number of other research firms have also commented on GLUE. Credit Suisse Group dropped their price target on shares of Monte Rosa Therapeutics to $12.00 in a research report on Wednesday, November 16th. UBS Group began coverage on shares of Monte Rosa Therapeutics in a research report on Thursday, October 13th. They issued a buy rating and a $22.00 price target on the stock.
許多其他研究公司也對 GLUE 進行了評論。瑞信集團在 11 月 16 日星期三的一份研究報告中,將羅莎治療學股票的價格目標降至 12.00 美元。瑞銀集團於 10 月 13 日(星期四)在一份研究報告中開始對蒙特羅莎治療學的股票進行報導。他們發布了買入評級和 22.00 美元的股票價格目標。
Monte Rosa Therapeutics Stock Down 0.6 %
蒙特羅莎治療股票下降 0.6%
Shares of GLUE opened at $7.70 on Monday. The firm's 50 day moving average price is $8.51 and its 200 day moving average price is $8.75. Monte Rosa Therapeutics has a twelve month low of $6.05 and a twelve month high of $18.16.
膠水股份週一以 7.70 美元開盤。該公司的 50 日移動平均價格為 8.51 美元,其 200 日移動平均價格為 8.75 美元。蒙特羅莎治療學有十二個月低點 6.05 美元和十二個月的高點 18.16 美元。
Institutional Investors Weigh In On Monte Rosa Therapeutics
機構投資者權衡蒙特羅莎治療
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Monte Rosa Therapeutics by 24.8% in the third quarter. Bank of New York Mellon Corp now owns 87,632 shares of the company's stock worth $716,000 after acquiring an additional 17,424 shares during the last quarter. Alphabet Inc. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $11,961,000. Balyasny Asset Management LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $155,000. Jane Street Group LLC acquired a new stake in Monte Rosa Therapeutics during the third quarter worth $410,000. Finally, State Street Corp boosted its stake in Monte Rosa Therapeutics by 7.5% during the third quarter. State Street Corp now owns 484,571 shares of the company's stock worth $3,959,000 after buying an additional 33,707 shares in the last quarter. Institutional investors and hedge funds own 83.19% of the company's stock.
幾家對沖基金和其他機構投資者最近修改了他們對該股票的持有量。紐約梅隆銀行在第三季度增加了 24.8% 的玫瑰治療學股份的股份。紐約梅隆銀行現在擁有該公司股票的 87,632 股,價值 716,000 美元,在上一季度額外收購 17,424 股。字母公司在第三季度收購了蒙特羅莎治療學的新股份,價值 11,961,000 美元。巴亞斯尼資產管理有限責任公司在第三季度收購了羅莎蒙特治療學的新股份 155,000 美元。簡街集團有限責任公司在第三季度收購了蒙特羅莎治療學的新股份,價值 410,000 美元。最後,州街公司在第三季度將其在羅莎山治療的股份提高了 7.5%。在上一季度額外購買 33,707 股後,州街公司現在擁有該公司股票的 484,571 股價值 3,959,000 美元。機構投資者和對沖基金擁有公司股票的 83.19%。
Monte Rosa Therapeutics Company Profile
蒙特羅莎治療公司簡介
(Get Rating)
(取得評分)
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
Monte Rosa Theraptics, Inc. 是一家生物製藥公司,致力於開發新型小分子精密藥物,該藥物利用人體的自然機制來選擇性地降解治療相關蛋白質。它開發了一種用於 GSPT1 的口服分子膠水降解劑,這是一種轉化終止因子和含脫氣蛋白質,用於治療 MYC 驅動的癌症。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
- Will Trade Desk Inc Bounce Off Its Support Line?
- 獲取有關玫瑰治療學(膠水)的研究報告的免費副本
- 床浴室及超越股票崩潰 24% 可能破產新聞
- 為什麼卡夫亨氏走高
- 這對德文能源今年的股價意味著什麼?
- 尼歐股票,這是底部嗎?
- 貿易台公司會反彈其支持線嗎?
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收玫瑰山治療日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關蒙羅莎治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧